Lauri Jouhi1, Elina Halme2, Heikki Irjala3, Kauko Saarilahti4, Petri Koivunen5, Matti Pukkila6, Jaana Hagström7,8, Caj Haglund9,8, Paula Lindholm10, Pasi Hirvikoski11, Samuli Vaittinen12, Anna Ellonen3, Jukka Tikanto5, Henry Blomster6, Jussi Laranne2, Reidar Grénman3, Antti Mäkitie1, Timo Atula1. 1. a Department of Otorhinolaryngology-Head and Neck Surgery , University of Helsinki, Helsinki University Hospital , Helsinki , Finland. 2. b Department of Otorhinolaryngology-Head and Neck Surgery , Tampere University Hospital, University of Tampere , Tampere , Finland. 3. c Department of Otorhinolaryngology-Head and Neck Surgery , Turku University Hospital, University of Turku , Turku , Finland. 4. d Department of Oncology , Helsinki University Hospital, University of Helsinki , Helsinki , Finland. 5. e Department of Otorhinolaryngology-Head and Neck Surgery , Oulu University Hospital, University of Oulu , Oulu , Finland. 6. f Department of Otorhinolaryngology-Head and Neck Surgery , Kuopio University Hospital, University of Eastern Finland , Kuopio , Finland. 7. g Department of Pathology , University of Helsinki, HUSLAB, Helsinki University Hospital , Helsinki , Finland. 8. i Research Programs Unit, Translational Cancer Biology , University of Helsinki , Helsinki , Finland. 9. h Department of Surgery , University of Helsinki, Helsinki University Hospital , Helsinki , Finland. 10. j Department of Oncology , Turku University Hospital, University of Turku , Turku , Finland. 11. k Department of Pathology , Oulu University Hospital, University of Oulu , Oulu , Finland. 12. l Department of Pathology , Turku University Hospital, University of Turku , Turku , Finland.
Abstract
BACKGROUND: Treatment for oropharyngeal squamous cell carcinoma (OPSCC) has changed, as the proportion of human papilloma virus (HPV)-related disease has increased. We evaluated nationwide information on its management and outcome during the treatment paradigm change period. METHODS: We included all patients diagnosed and treated for OPSCC at the five Finnish university hospitals from 2000 to 2009. Patient records and pathology registries provided the clinicopathological data. p16 staining was performed on primary tumor samples of patients who had received treatment with curative intent. RESULTS: A total of 674 patients were diagnosed and treated for OPSCC and the incidence increased along the study period. Of the evaluable tumors 58.5% were p16-positive and the number of p16-positive tumors increased along the years. The treatment was given with curative intent for 600 patients and it was completed in 564. Of them, 47.9% underwent primary surgery and 52.1% received definitive oncological treatment. Also, the treatment protocol changed towards a more oncological approach. Among patients treated with curative intent the five-year overall, disease-specific and disease-free survival rates were 60.1, 71.5 and 57.0%. In multivariate analysis, p16-positivity seemed to relate to reduced disease mortality in lateral and anterior-wall disease. Depending on primary tumor localization, also sex, classes T3-4, presence of regional metastasis and radiotherapy modality had an association with disease mortality. CONCLUSION: The incidence of p16-positive OPSCC and delivery of definitive oncological treatment increased in Finland during the study period. An improved survival outcome compared with the previous nationwide investigation was observed in this subset of patients.
BACKGROUND: Treatment for oropharyngeal squamous cell carcinoma (OPSCC) has changed, as the proportion of human papilloma virus (HPV)-related disease has increased. We evaluated nationwide information on its management and outcome during the treatment paradigm change period. METHODS: We included all patients diagnosed and treated for OPSCC at the five Finnish university hospitals from 2000 to 2009. Patient records and pathology registries provided the clinicopathological data. p16 staining was performed on primary tumor samples of patients who had received treatment with curative intent. RESULTS: A total of 674 patients were diagnosed and treated for OPSCC and the incidence increased along the study period. Of the evaluable tumors 58.5% were p16-positive and the number of p16-positive tumors increased along the years. The treatment was given with curative intent for 600 patients and it was completed in 564. Of them, 47.9% underwent primary surgery and 52.1% received definitive oncological treatment. Also, the treatment protocol changed towards a more oncological approach. Among patients treated with curative intent the five-year overall, disease-specific and disease-free survival rates were 60.1, 71.5 and 57.0%. In multivariate analysis, p16-positivity seemed to relate to reduced disease mortality in lateral and anterior-wall disease. Depending on primary tumor localization, also sex, classes T3-4, presence of regional metastasis and radiotherapy modality had an association with disease mortality. CONCLUSION: The incidence of p16-positive OPSCC and delivery of definitive oncological treatment increased in Finland during the study period. An improved survival outcome compared with the previous nationwide investigation was observed in this subset of patients.
Authors: Timo Carpén; Stina Syrjänen; Lauri Jouhi; Reija Randen-Brady; Caj Haglund; Antti Mäkitie; Petri S Mattila; Jaana Hagström Journal: Cancer Immunol Immunother Date: 2020-04-20 Impact factor: 6.968
Authors: Antti A Mäkitie; Harri Keski-Säntti; Mari Markkanen-Leppänen; Leif Bäck; Petri Koivunen; Tomas Ekberg; Karl Sandström; Göran Laurell; Mathias von Beckerath; Johan S Nilsson; Peter Wahlberg; Lennart Greiff; Lena Norberg Spaak; Thomas Kjærgaard; Christian Godballe; Oddveig Rikardsen; Hani Ibrahim Channir; Niclas Rubek; Christian von Buchwald Journal: Front Oncol Date: 2018-07-27 Impact factor: 6.244
Authors: Amy Dickinson; Mayank Saraswat; Stina Syrjänen; Tiialotta Tohmola; Robert Silén; Reija Randén-Brady; Timo Carpén; Jaana Hagström; Caj Haglund; Petri Mattila; Antti Mäkitie; Sakari Joenväärä; Suvi Silén Journal: PLoS One Date: 2020-06-15 Impact factor: 3.240